Skip to main content

Table 4 Median risk ratio for each treatment compared against placebo in all five network meta-analyses

From: Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups

Treatment

Median risk ratio versus placebo–PASI 75 (95% CrI)

All licensed doses

No previous biologic use (< 25%)

PASI score ≤ 25

Weight ≤ 90 kg

≥ 90% white patients

Adalimumab 40 mg

12.74 (11.00–14.49)

12.48 (10.91-14.13)

13.09 (11.72-14.57)

12.87 (10.29-15.39)

13.18 (11.21-15.15)

Brodalumab 210 mg

16.76 (15.12–18.53)

16.45 (14.66–18.31)

16.62 (15.20–18.18)

16.73 (14.97–18.58)

16.56 (15.02–18.24)

Certolizumab 200 mg

12.07 (9.62–14.54)

13.93 (8.63–18.20)

12.08 (10.30–13.94)

11.71 (9.11–14.27)

12.13 (10.02–14.26)

Certolizumab 400 mg

13.47 (11.09–15.80)

15.73 (10.81–19.08)

13.42 (11.65–15.23)

13.04 (10.53–15.46)

13.48 (11.42–15.52)

Etanercept 25 mg

7.61 (5.52–10.11)

7.64 (6.20–9.20)

7.89 (5.60–10.51)

Etanercept 50 mg once–weekly

10.67 (7.96–13.53)

5.08 (3.50–7.07)

6.16 (4.69–7.90)

5.57 (3.91–7.65)

7.07 (4.57–10.20)

Etanercept 50 mg twice per week

9.90 (8.68–11.21)

9.46 (8.27–10.77)

10.40 (9.47–11.40)

9.85 (8.27–11.55)

10.33 (9.01–11.75)

Guselkumab 100 mg

17.06 (15.30–18.91)

16.68 (15.07–18.42)

16.83 (15.32–18.46)

15.30 (10.89–18.39)

Infliximab 5 mg

16.22 (14.37–18.15)

16.88 (14.66–19.03)

15.46 (13.85–17.17)

14.19 (11.76–16.56)

15.38 (13.41–17.36)

Ixekizumab 80 mg

17.64 (16.06–19.36)

17.42 (15.89–19.09)

17.79 (16.30–19.41)

17.16 (14.67–19.33)

17.75 (16.23–19.41)

Risankizumab 150 mg

16.46 (14.37–18.47)

Secukinumab 300 mg

16.45 (14.79–18.23)

16.03 (14.41–17.73)

16.43 (15.03–17.96)

16.12 (14.55–17.82)

18.67 (16.22–20.81)

Ustekinumab 45 mg

13.59 (11.79–15.44)

12.20 (10.32–14.14)

13.46 (12.17–14.84)

13.04 (10.35–15.63)

13.68 (11.95–15.48)

Ustekinumab 90 mg

14.67 (12.85–16.54)

13.36 (11.29–15.38)

14.51 (13.20–15.95)

14.36 (10.18–17.57)

14.64 (13.00–16.37)

Ustekinumab (45 mg or 90 mg)

12.85 (11.07–14.67)

12.96 (11.05–14.94)

13.19 (11.79–14.66)

13.11 (10.99–15.20)

13.14 (11.35–14.95)

Tildrakizumab 100 mg

14.86 (12.49–17.02)

15.03 (13.18–16.91)

15.82 (14.25–17.50)

15.28 (13.31–17.21)

16.21 (14.20–18.16)

Apremilast

5.80 (4.20–7.61)

3.77 (2.48–5.59)

5.17 (4.01–6.61)

3.91 (2.60–5.79)

5.46 (4.12–7.10)

Dimethyl Fumarate

2.97 (1.44–5.73)

2.97 (1.77–4.88)

2.97 (1.71–5.01)

2.96 (1.71–4.98)

Fumaderm

3.31 (1.62–6.26)

3.32 (1.97–5.41)

3.31 (1.94–5.53)

3.30 (1.92–5.48)

Methotrexate

6.15 (4.07–8.65)

10.47 (6.73–14.41)

6.50 (4.69–8.60)

5.49 (3.56–8.12)

6.30 (4.37–8.61)

Acitretin

4.024 (1.55–8.39)

4.07 (1.59–8.29)

4.29 (1.74–8.43)

Cyclosporin 1.5 mg

8.10 (2.41–16.91)

2.14 (0.38–10.53)

Cyclosporin 2.5 mg

7.10 (2.02–16.34)

6.76 (2.07–16.03)